Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Total Non-Current Liabilities (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 5 years of Total Non-Current Liabilities data on record, last reported at $1.6 billion in Q3 2025.

  • For Q3 2025, Total Non-Current Liabilities changed N/A year-over-year to $1.6 billion; the TTM value through Sep 2025 reached $1.6 billion, changed N/A, while the annual FY2024 figure was $1.6 billion, 14.5% down from the prior year.
  • Total Non-Current Liabilities reached $1.6 billion in Q3 2025 per INDV's latest filing, up from $239.0 million in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $1.9 billion in Q4 2023 and bottomed at -$413.0 million in Q4 2022.
  • Average Total Non-Current Liabilities over 5 years is $924.1 million, with a median of $1.2 billion recorded in 2021.
  • Peak YoY movement for Total Non-Current Liabilities: plummeted 133.39% in 2022, then soared 562.71% in 2023.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $1.2 billion in 2021, then tumbled by 133.39% to -$413.0 million in 2022, then skyrocketed by 562.71% to $1.9 billion in 2023, then dropped by 14.5% to $1.6 billion in 2024, then dropped by 2.51% to $1.6 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $1.6 billion in Q3 2025, $239.0 million in Q2 2025, and $268.0 million in Q1 2025.